Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06149260
Other study ID # LYG2022061
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 29, 2024
Est. completion date December 2024

Study information

Verified date March 2024
Source Second Xiangya Hospital of Central South University
Contact Rong Xiao, MD
Phone 13808425555
Email xiaorong65@csu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis


Description:

Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the cardiac, pulmonary, and gastrointestinal systems. This is a small prospective and open-label clinical trial of semaglutide in adults with systemic slceorsis. 10 systemic sclerosis patients will be recruited and receive semaglutide for 24 weeks. The primary endpoint of the study is the change in mRSS at 24 weeks of treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 2024
Est. primary completion date August 29, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:(Those who have not achieved good results after hormone or immunosuppressive therapy) 1. Gender unlimited; 2. Age 18-65 years old (including 65 years old); 3. Patients diagnosed with SSc who meet the 2013 European Union Against Rheumatology (EULAR)/American Society of Rheumatology (ACR) SSc diagnostic classification criteria and exclude infections, tumors, and other connective tissue diseases. 4. Has received one or more of the following standard systemic treatments allowed by the research protocol: 1. Before the first subcutaneous injection of the study, oral corticosteroids (prednisone not exceeding 15mg/d or equivalent) were administered for = 8 weeks, and stabilizers were administered for = 4 weeks. 2. Before the first subcutaneous injection of the study, patients were treated with Tofacitinib (5-10mg/d) for = 8 weeks and received a stabilizer dose for = 6 weeks. 3. If one or more of the following immune modulators are used, treatment must be given for = 12 weeks before the start of the study, and treatment with a stabilizer dose must be given for = 6 weeks Oral mycophenolate mofetil (MMF) = 1.5 g/day Methotrexate (MTX) oral = 15 mg/week, combined with folic acid Cyclosporine If the subjects use = 2 of the above immunomodulatory drugs in combination, the appropriateness of the subjects' participation in the study must be discussed with the medical supervisor and study chair before enrollment. 5. A modified Rodnan Skin Score (mRSS) of > 14 6. Those who sign an informed consent form, voluntarily participate in this project, and are able to complete follow-up as required. Exclusion Criteria: 1. Prior to the first dose, Body Mass Index (BMI) < 18.5 kg/m2; weight loss of 10% within one month or 20% within six months. 2. Family or personal history of type 2 multiple endocrine neoplasia or medullary thyroid carcinoma, with family history involving first-degree relatives. 3. History of malignant tumors or a history of malignant tumors within the past 5 years before screening. 4. Presence of other inflammatory diseases that may interfere with efficacy assessment, including but not limited to rheumatoid arthritis (RA), overlap syndrome, psoriasis, dermatomyositis, multiple sclerosis, Crohn's disease, or active Lyme disease. 5. Severe gastrointestinal complications of systemic sclerosis (SSc), such as significant swallowing difficulties, and severe diseases affecting vital organ systems such as the heart, brain, lungs, liver, kidneys, or blood, as deemed unsuitable for participation in the study by the investigator. 6. Known current active or recurrent severe infections, including active tuberculosis. 7. Congenital immunodeficiency or congenital immunosuppression. 8. Substance abuse, alcoholism, or psychiatric disorders, rendering patients uncooperative or unable to adhere to treatment; poor predictability of compliance. 9. Women who are pregnant, breastfeeding, or planning to become pregnant. 10. Patients currently participating in other clinical trials.

Study Design


Intervention

Drug:
Semaglutide Pen Injector
Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.

Locations

Country Name City State
China the Second Xiangya Hospital Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Second Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in modified Rodnan skin score (mRSS) at week 24 Change in modified Rodnan skin score (mRSS) at week 24 performed by the same investigator at week 0 and week 24 and the change in mRSS will be calculated following the formula: ?mRSS= mRSSw24 - mRSSw0.
To measure mRSS, skin thickness of the patient is rated by palpation at each of 17 anatomic sites using a scale of 0-3 (0 = normal skin; 1= mild thickness; 2= moderate thickness; 3=severe thickness with an inability to pinch the skin into a fold). The scores at each site are summed with a minimum of 0 and a maximum of 51 (17 sites)
Baseline and 24 weeks
Secondary Incidence of Adverse Events Baseline and 24 weeks
Secondary Incidence of Severe Adverse Events Baseline and 24 weeks
Secondary the scleroderma health assessment questionnaire-disability index (sHAQ-DI) Baseline and 24 weeks
Secondary High-resolution computer tomography (HRCT) Baseline and 24 weeks
Secondary Forced Vital Capacity(FVC) and Diffusing capacity of the lung for carbon monoxid(DLCO) Baseline and 24 weeks
Secondary St George' s Respiratory Questionnaire(SGRQ) Baseline and 24 weeks
Secondary Pulmonary arterial hypertension by echocardiography Baseline and 24 weeks
Secondary left ventricular ejection fraction by echocardiography Baseline and 24 weeks
Secondary 6-Minute Walk Test (6MWT) Distance Baseline and 24 weeks
Secondary gastrointestinal tract (GIT) in scleroderma score Baseline and 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05570058 - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979417 - Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
Completed NCT02408744 - Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease Phase 1/Phase 2
Active, not recruiting NCT00148837 - Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis Phase 2
Recruiting NCT05661123 - Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis N/A
Recruiting NCT04795570 - Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
Active, not recruiting NCT05075785 - Covid-19 Respiratory Sequelae French Cohort
Recruiting NCT03308916 - Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers N/A
Recruiting NCT05459259 - Physiotherapy for Arthrofibrosis Following Knee Replacement.
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00001729 - Combination Drug Therapy for Patients With Hepatitis C Phase 3
Completed NCT02049307 - Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial Phase 2
Active, not recruiting NCT05685823 - The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
Completed NCT00744939 - Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Phase 4
Completed NCT00252642 - Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C N/A
Recruiting NCT04934202 - Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
Completed NCT02604862 - Imaging FIB ONE in the Human Lung Using Endomicroscopy Early Phase 1
Completed NCT02774161 - B-mode Ultrasound Imaging in Detecting Early Liver Cancer N/A
Active, not recruiting NCT01246388 - Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy N/A
Completed NCT02161952 - Pirfenidone, an Antifibrotic and Antiinflammatory Drug Phase 2